Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SST-024
- Development stage
- Preclinical
- Lead developer
- StemSynergy Therapeutics
- Modality
- Small Molecules
01
Overview
SST-024 is a first-in-class small molecule modulator of the Wnt signaling pathway, specifically targeting Casein Kinase 1 alpha (CK1α). Developed by StemSynergy, it is currently in the lead optimization stage of preclinical development for the treatment of Familial Adenomatous Polyposis (FAP). By modulating CK1α activity, SST-024 aims to regulate the aberrant Wnt signaling that drives the formation of numerous precancerous polyps in the colon and rectum of patients with FAP, potentially preventing the progression to colorectal cancer. The compound is part of a broader pipeline of Wnt, Notch, and Myc pathway modulators developed using SSTI chemistry.
02
Targets
CK1α (Casein kinase I alpha)
Beyond the preview
Go deeper on SST-024.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SST-024.